ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics The Alzheimer’s Drug Discovery Foundation announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. to judge small-molecule, orally delivered Protein Phosphatase 2a -modulatory compounds as disease-modifying therapeutics for Alzheimer’s disease. Related StoriesGriffith University uncovers first 3-D image of proteins associated with cancer spreadStudy reveals system behind protein-related diseasesUnderstanding how schizophrenia impacts workings of the brainSignum is certainly developing lipid transmission transduction modulators for chronic neurodegenerative and inflammatory illnesses.Pollard. Further it offers another chance for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It offers us another prong in the strike on malignancy. Dr. Pollard is usually deputy director of the Albert Einstein Cancers Middle, director of the Center for Research of Reproductive Biology and Women’s Health and the Louis Goldstein Swan Chair in Women’s Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women’s wellness at Einstein and Montefiore Medical Center. This award from the American Cancers Society, the nation’s leading voluntary health firm and largest non-governmental investor in cancer analysis, represents the Society’s highest honor in recognition of outstanding contributions to fighting malignancy.